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Abstract Mutations to the ubiquitous antioxidant en-
zyme Cu/Zn superoxide dismutase (SOD1) were the
first established genetic cause of the fatal, adult-onset
neurodegenerative disease amyotrophic lateral sclerosis
(ALS). It is widely accepted that these mutations do
not cause ALS via a loss of antioxidant function, but
elucidating the alternate toxic gain of function has prov-
en to be elusive. Under physiological conditions, SOD1
binds one copper ion and one zinc ion per monomer to
form a highly stable and functional homodimer, but
there is now ample evidence to indicate aberrant persis-
tence of SOD1 in an intermediate metal-deficient state
may contribute to the protein’s involvement in ALS.
This review briefly discusses some of the data to sup-
port a role for metal-deficient SOD1 in the development
of ALS and some of the outcomes from drug develop-
ment studies that have aimed to modify the symptoms
of ALS by targeting the metal state of SOD1. The implica-
tions for the metal state of SOD1 in cases of sporadic ALS that
do not involve mutant SOD1 are also discussed.
Keywords Amyotrophic lateral sclerosis (ALS) .Motor
neuron disease (MND) . Copper (Cu) . Zinc (Zn) . Cu/Zn
superoxide dismutase (SOD1) . Proteinmisfolding .
Diacetylbis(4-methylthiosemicarbazonato)copperII
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease that selectively afflicts the motor neu-
rons in the spinal cord, motor cortex and brainstem
leading to their dysfunction and eventual death [1].
The loss of functional motor neurons and associated
clinical symptoms in ALS is progressive, and despite
variability in timeframes relative to clinical subtype,
ALS ultimately causes paralysis and premature death
which is generally due to respiratory failure. In general,
the peak age of onset is 45–60 years, and survival post
diagnosis in the vicinity of 3–5 years.
The predominant proportion of ALS cases is
characterised as sporadic, with only 5–10 % of cases
presenting with a known heritable genetic basis [2].
The most prominent and well-understood genetic basis
for familial ALS concerns point mutations to the ubiq-
uitously expressed antioxidant enzyme superoxide dis-
mutase 1 (SOD1) [3]. SOD1 mutations were the first
described genetic cause of ALS [4] and are accordingly
the most widely studied. They may present as missense
mutations or frameshift mutations leading to protein
truncation and can reside throughout the protein includ-
ing within key catalytic and structural regions such as
the metal-binding regions and dimer interface [5]. SOD1
mutations are typically segregated into two distinct
groups termed the Bwild-type-like^ mutants (G37R,
G93A, A4V, etc.), which retain similar properties to
wild-type SOD1, and the metal-binding region mutants
(G85R, H46R, etc.), characterised by vastly different
biophysical attributes related to metal binding, SOD1
enzymatic activity and spectroscopy [6–9]. But despite
gaining good research attention over the past two de-
cades, the definitive mechanisms by which SOD1 muta-
tions cause ALS are yet to be fully elucidated.
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Mutant SOD1 rodent models of ALS
As SOD1 plays a vital role as an antioxidant converting su-
peroxide (O2.
−) into hydrogen peroxide (H2O2) for subsequent
breakdown by glutathione peroxidase and catalase into water
[10], it was initially suspected that a loss of function may
contribute to ALS pathogenesis. This hypothesis was subse-
quently rejected since SOD1 knockout mice failed to develop
an ALS-like phenotype [11]. These mice did display an in-
creased motor neuron sensitivity to axonal injury [11] and
pathology in response to paraquat induced of oxidative stress
[12], demonstrating the clear requirement for SOD1 in
protecting motor neurons from adverse insults, but they also
provided early evidence that a loss of SOD1 function in iso-
lation is not a sole contributor to ALS in mutant SOD1 cases
of the disease. Thus, in the absence of an overt phenotype in
the SOD1 knockout mice, the main contention is that a toxic
gain of function is fundamentally responsible for the develop-
ment of ALS in cases where SOD1 mutations are involved.
To more thoroughly investigate the role played by the myriad
SOD1 mutants discovered in ALS, various rodent models of the
disease have been generated by overexpressing human SOD1
containing different point mutations. The initial mutant SOD1
rodent models were developed soon after mutant SOD1 was
identified as a cause of ALS in humans, and depending on the
form and amount of mutant SOD1 expressed, the rate of disease
progression and lifespan of these animals varies considerably
[13, 14]. Although the overexpression of mutant human SOD1
in these animals is not an ideal representation of disease condi-
tions in ALS, due to reliance on overexpression of an exogenous
gene, these animals nonetheless provide a useful and widely
available model for disease investigation. Furthermore, the de-
velopment of transgenic rodents overexpressing the wild-type
form of humanSOD1has provided the opportunity to investigate
specific differences between mutant and wild-type SOD1 within
the constraints of an overexpression model. Wild-type SOD1-
overexpressing mice are generally used as a negative control line
due to the absence of an overt ALS-like phenotype in the hemi-
zygous, wild-type SOD1-expressing mice, particularly when
compared to age-matched mutant SOD1 expressing mice. How-
ever, wild-type SOD1-expressing mice have nonetheless provid-
ed some evidence to implicate a role for SOD1 in cases of ALS
that do not involve mutant SOD1; subtle phenotype changes
have been reported for hemizygous, wild-type SOD1-overex-
pressing mice at a relatively young age [15], whereas a more
recent study has described pronounced ALS-like features in ho-
mozygous, wild-type SOD1-overexpressing mice [16].
SOD1 aggregates
The discovery of insoluble aggregates of SOD1 in mutant
SOD1 mouse models of ALS [17] and human cases of ALS
[18, 19] led to the postulation that the formation of these
aberrant inclusions may represent the toxic gain-of-function
mechanism through which SOD1-induced motor neuron
death occurs. The production of metal-deficient monomeric
species destabilised in a disulphide bond reduced state aided
through mutations could present a pathway through which
insoluble aggregates can form [20, 21]. Ubiquitin detected
within the aggregates [22] suggested that these insoluble in-
clusions were marked for proteasomal degradation which may
have been impeded, perhaps through overloading of the
ubiquitin-proteasome system [23]. Moreover, the detection
of other proteins such as chaperones within the aggregates
[24] indicated the possibility of a secondary loss-of-function
disease mechanism through which various proteins become
aberrantly sequestered and co-localise within the SOD1 ag-
gregates [25]. The fact that observable insoluble aggregates
were typically present at late stages in the disease progression
[26], however, suggested that aggregates are likely to be a
downstream consequence of alternative pathological process-
es. With the advent of monoclonal antibodies designed to bind
the putative toxic misfolded species of SOD1, attention has
shifted towards a soluble form of misfolded SOD1 which was
reported to be detectable across all ages in mutant SOD1 ex-
pressing murine spinal cord tissue [27]. Supporting this find-
ing, it was observed that co-expression of mutant and wild-
type human SOD1 increased the solubility of mutant
misfolded SOD1 species leading to greater cellular toxicity
[28], demonstrating that the soluble form may be an earlier
contributor to ALS pathogenesis whilst aggregate formation
may represent a cellular defence mechanism [28].
Zinc-deficient SOD1
Once translated, the incipient monomeric polypeptide of
SOD1 becomes bound to one zinc atom providing structural
integrity before the direct interaction with copper chaperone
for superoxide dismutase (CCS) which ensures the binding of
a copper atom required for catalytic activity [29]. The estab-
lishment of a fully functional SOD1 enzyme then occurs
through intramolecular disulphide bond formation and com-
bination with another monomeric protein to create the func-
tional homodimer [30]. The fact that many disparate point
mutations within SOD1 can induce ALS led to the hypothesis
that an impaired folding mechanism may be responsible for
producing aberrant copper-mediated chemistry. Changes in
SOD1 protein folding due to mutations may allow aberrant
substrate access to the copper-dependent catalytic region lead-
ing to potentially harmful reactions. Furthermore, impairment
in copper-binding capacity may promote its release where it
could catalyse reactions that cause oxidative damage [31]. An
initial substrate proposed to induce cellular pathology was
peroxynitrite [32] which is created spontaneously through
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interaction between nitric oxide (NO) and O2.
−, leading to
tyrosine nitration of proteins capable of interfering with cellu-
lar pathways. However, the fact that the G85R SOD1 muta-
tion causes rapidly progressing disease without retaining
copper-dependent enzymatic activity [33, 34], in conjunction
with studies showing co-expression of wild-type SOD1—
which would be expected to ameliorate peroxynitrite dam-
age—worsens disease progression [35], have made this a less
likely hypothesis. The ability for H2O2 to induce peroxidation
damage on cellular components and its central position within
the antioxidant role of SOD1 provided another popular candi-
date for the SOD1-dependent toxic species. But, the same
limitations apply as for the peroxynitrite hypothesis where
SOD1G85R mutations induce an ALS phenotype indepen-
dent of aberrant copper chemistry, with further evidence dem-
onstrating an inability to detect elevated levels of H2O2 in
mutant SOD1 models [36].
Zinc is crucial for the structural integrity of SOD1 and
possesses a curiously weaker affinity than copper [37],
prompting the suggestion that a zinc-deficient species of
SOD1 may contribute to ALS (Fig. 1). It has been reported
that mutant forms of SOD1 have a decreased affinity for the
structural zinc atom in contrast to the wild-type species [38],
presumably affecting the protein folding pattern and indirectly
affecting the catalytic activities of SOD1. Changes to the na-
tive zinc binding site lead to increased zinc loss from SOD1
which subsequently becomes more relaxed and potentially
more accessible to substrates able to catalyse nitration reac-
tions. Additionally, through a shared bridging histidine resi-
due [39], the consequence of zinc deficiencymay be to change
the redox state of the bound copper which could facilitate
protein nitration [37]. Neurofilaments and metallothioneins
bind readily to metals [40, 41] and are present in large cellular
concentrations similar to SOD1, so it has been proposed that
these proteins may act as a sink for zinc, leading to greater
zinc-deficient SOD1 levels and therefore increased
peroxynitrite-dependent nitration reactions [37, 42]. Due to
reported similarities in the binding affinity for zinc between
mutant SOD1 and the wild-type form, it has been contended
that there may exist the capacity for wild-type SOD1 to be-
come zinc deficient in sporadic cases of ALS as well [38, 43].
More recently, it was reported that zinc-deficient SOD1 is
required to induce motor neuron death with copper chelation
acting to protect motor neurons from nitric oxide-induced
death and the addition of fully metallated wild-type SOD1
acting to increase toxicity in the presence of NO; it was dem-
onstrated that the fully metallated monomer of wild-type
SOD1 could form a dimer with a zinc-deficient monomer of
mutant SOD1, thereby stabilising the zinc-deficient mono-
meric species and exacerbating its toxicity in the presence of
NO [44].
Initial studies on zinc supplementation as a treatment for
mutant SOD1 mice demonstrated an increase in the rate of
death [45]. A follow-up study however attributed this outcome
to excessive zinc treatment leading to competition for copper
absorption that ultimately inhibited ceruloplasmin resulting in
fatal anaemia [46]. An amended treatment programme using a
more modest zinc supplement concentration conversely dem-
onstrated an improved survival rate in the same mouse model
of ALS [46]. Whilst the zinc-deficient SOD1 induction of
peroxynitrite-dependent pathology is widely supported, con-
tradictory evidence exists for the relevance of tyrosine nitra-
tion in most SOD1 mutant models as well as human ALS
cases [36, 47]. Considering the requirement of NO for
peroxynitrite production, the abatement of nitric oxide syn-
thase (NOS) generators of NO would be expected to amelio-
rate disease symptoms. Yet the pharmacological inhibition of
neuronal NOS [48] and genetic ablation of inducible NOS
[49] failed to have an effect on the survival of SOD1 mutant
mice, casting some doubt upon the peroxynitrite hypothesis.
Copper-deficient SOD1
As an alternative to zinc-deficient SOD1 driving toxicity in
specific models of familial ALS, a role for a copper-deficient
species has been mooted (Fig. 1). SOD1 has one of the
greatest affinities for copper, alongside metallothioneins, with
a reported ∼7000 times greater affinity for copper than zinc in
the case of wild-type SOD1 that was increased further in A4V
SOD1mutants [43]. As previouslymentioned, the SOD1 loss-
of-function hypothesis was rejected based on an absence of
ALS-like pathology in SOD1 knockout mice, demonstrating
that a loss of copper-dependent dismutase activity in isolation
does not cause ALS [12]. Additionally, when endogenous
mouse SOD1 was knocked out in mice expressing the
metal-binding region SOD1G85R mutant—which exhibits
extremely poor metal-binding properties [50]—there was no
Fig. 1 Overview of various
forms of SOD1 relative to metal
state, the potential contribution of
metal-deficient SOD1 to ALS and
therapeutic opportunity to
attenuate toxicity of metal-
deficient SOD1
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difference in survival or age of symptom onset [51]. Work
performed on the wild-type-like SOD1G37R mutant de-
scribed above conversely demonstrated dismutase activity
levels that were unchanged relative to wild-type SOD1, yet
induced an ALS-like phenotype when expressed in transgenic
mice [52]. Subsequent work investigating the metallation sta-
tus of mutant SOD1 species found that whilst metal-binding
region SOD1 mutants were severely metal deficient, wild-
type-like mutant SOD1 species exhibited normal activity
levels per equivalent copper but a detectable decrease in metal
binding capacities relative to wild-type control [7]. This was
supported through computational analysis performed on the
SOD1G37R mutant which showed that this point mutation,
which is not within the metal binding region, could also in-
duce metal binding impairment leading to decreased copper
affinity ahead of zinc based on free energy calculations [53].
Several studies, utilising copper chelating compounds in
SOD1 mutant models of ALS intended to inhibit the purport-
edly aberrant copper chemistry, have reported protection
against motor neuron loss with a corresponding improvement
in lifespan and locomotor function [54–56]. The mechanisms
of action for therapeutic benefit suggested attenuation of cop-
per ion toxicity [55], decreased spinal cord copper ion levels
and reduced lipid peroxidation [56], or decreased markers of
oxidative damage and inflammation [54]. Contrarily, previous
work on the successful imaging compound diacetylbis(4-
methylthiosemicarbazonato)copperII [57] demonstrated that
under conditions of impaired mitochondrial transport chain
function and elevated NADH levels, treatment with
CuII(atsm) increased intracellular retention of copper [58].
When used to treat a SOD1G93A mouse model of ALS, the
compound significantly delayed locomotor deficit onset and
improved survival, decreased levels of peroxynitrite-induced
protein nitration and increased SOD1 activity in spinal cord
tissue [57]. Collectively, these studies indicated that a thera-
peutic agent capable of increasing copper bioavailability could
protect against mutant SOD1 toxicity, a possibility consistent
with previous in vitro studies which had described the poten-
tial for copper deficiency to promote SOD1 pathology via
increased misfolding and altered hydrophobicity [59, 60]. It
was however a more recent study [61] involving CuII(atsm)
treatment in a SOD1G37R mouse model of ALS that illustrat-
ed the potential link between copper-deficient SOD1 and ALS
pathogenesis in vivo. Oral treatment with the compound again
showed improved locomotor function and prolonged survival
compared to untreated mice, concomitant with decreased mo-
tor neuron death within the spinal cords of treated mice. Using
a FTICR mass spectrometry technique [62, 63], it was shown
that zinc-deficient mutant SOD1 levels in both treated and
untreated mutant mice were relatively low (∼1 μM), in con-
trast to the substantially more abundant (∼60 μM) copper-
deficient form of the protein. Treatment with CuII(atsm) in-
duced a significant decrease in the levels of metal-deficient
mutant SOD1 and a corresponding increase in fully metallated
holo form of the protein. Changes to the metal-deficient pool
correlated directly to changes in the copper-deficient pool. It
was proposed that the CuII(atsm) treatment delivered copper
directly to the mutant SOD1, and this was supported by an
experiment in which the mice were treated with isotopically
labelled 65CuII(atsm). Due to conversion of the metal-deficient
SOD1 to the highly stable holo form, total levels of mutant
SOD1 were increased in the CuII(atsm)-treated mice. Based
on the fact that the phenotype of these mice was improved by
the CuII(atsm) treatment, despite an overall increase in levels
of mutant SOD1, it was concluded that the metal state of the
SOD1 is a greater determinant of the protein’s role in motor
neuron death and the ALS-like phenotype of these animals
than the mutant amino acid sequence per se. Interestingly,
the overall increase in SOD1 levels in the CuII(atsm)-treated
mice also included an increase in levels of the protein detected
using antibodies selective for the misfolded species [61].
Taken together, these results indicate that improving the
copper bioavailability within the spinal cord tissue of SOD1
mutant mice and improving SOD1metallation status are poten-
tial mechanisms for attenuating the ALS phenotype. Further-
more, since the unmetallated apo form of SOD1 is rapidly
turned over [64] and the fully metallated form is stable and
likely to be non-toxic regardless of amino acid substitution
mutations [65–68], it appears that a partially metal-deficient
intermediate species may be responsible for the SOD1 toxic
gain of function. This could potentially explain the contradic-
tory data in the literature reporting therapeutic benefits from
both copper chelating compounds and Bcopper delivery
agents^, both of which may be acting to shift the equilibrium
away from this potentially toxic copper-deficient species of
SOD1 (Fig. 1). It is currently not clear why such a large pool
of copper-deficient SOD1 would accumulate within the spinal
cord tissue of SOD1G37R mice, but outcomes from the
SOD1G93A mouse model have demonstrated that widespread
and progressive impairment of intracellular copper trafficking
occurs due to expression of the mutant SOD1 and that these
changes to copper trafficking can be detected at a presymptom-
atic stage [69]. Thus, it is apparent that copper homeostasis is
substantially altered by the expression of mutant SOD1 and that
therapeutically modulating copper bioavailability can attenuate
ALS-like symptoms in mutant SOD1 mice.
Definitive mechanistic data to support altered copper ho-
meostasis as a valid therapeutic basis for treating ALS in the
clinic, particularly sporadic cases of the disease, are yet to be
reported. However, mutations to the copper transporter
ATP7A that lead to systemic copper deficiency are an
established cause of the infantile-onset neurodegenerative
Menkes disease [70, 71], and some ATP7A missense muta-
tions have been shown to cause X-linked distal hereditary
motor neuropathies in the absence of systemic copper defi-
ciency [72]. This suggests that motor neurons may be
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particularly sensitive to altered copper homeostasis, and this
has been supported recently by a report describing a degener-
ative phenotype (involving progressive muscular atrophy, loss
of motor neuron cell bodies and denervation of the neuromus-
cular junction) in mice caused by selective knockout of the
Atp7a gene from motor neurons [73]. Although such an ex-
plicit role for altered copper homeostasis as a cause of ALS is
not yet evident, these studies nonetheless indicate the funda-
mental requirement for copper in maintaining motor neuron
functionality.
Concluding remarks
After more than 20 years of research since SOD1 mutations
were discovered as a definitive cause of ALS, the mechanisms
bywhich SOD1 cause ALS remain far from elucidated. Trans-
genic SOD1 animal models that develop robust ALS-like phe-
notypes have been created and have been used extensively for
preclinical drug development, but instead of providing clear
insight to the pathogenesis of ALS, these animal models have
often been the source of apparent confounding outcomes. But
progress in being made and the role for the metal state of
SOD1 in ALS is one area of research providing new opportu-
nity for the development of effective therapeutic options. It is
becoming clear that the metal state of SOD1 can be modulated
via therapeutic intervention and that the metal state of SOD1
may be a greater determinant of the protein’s elusive toxic
gain of function than the disease-causing mutations them-
selves. Further to this, evidence for a toxic gain of function
and structural instability in metal-deficient wild-type SOD1
indicates a mechanism by which SOD1 contributes to cases
of ALS that do not involve SOD1 mutations. Whether or not
metal-deficient wild-type SOD1 contributes to the pathogen-
esis of sporadic ALS is yet to be established, but if proven
could provide opportunity to treat all cases of ALS, not just
mutant SOD1 cases, using drugs designed to improve the
protein’s metal state.
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